InvestorNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Abstract Selected for Presentation at Sixth Annual Neuropsychiatric Drug Development Summit

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, will be presenting at the Neuropsychiatric Drug Development Summit, slated for Oct. 11–12, 2023, in Boston. Cybin’s abstract, titled “Structure-activity of 2C-X psychedelics to develop a novel 5-HT2A receptor full agonist with therapeutic potential,” was chosen to be presented during the premier gathering. The presentation is scheduled for Oct. 11, 2023, at 5 p.m. ET. The abstract describes a comprehensive structure-activity relationship study of a series of novel serotonergic phenethylamines and summarized CYBN’s studies that identified multiple potential compounds of therapeutic potential with attractive drug-like characteristics, including good safety profile, high oral bioavailability and brain penetration.

In addition to reporting on the abstract, company officials will also moderate a psychedelic workshop titled, “Making Psychedelic Clinical Trials a Reality: Mitigating Practical Burdens of Time, Investment & Reimbursement.” The workshop will begin at 9 a.m. ET on Oct. 10, 2023. The workshop will include topics such as optimizing clinical trial design, addressing the need for monitoring in psychedelic trials, and the potential therapeutic advantages and durability of short-acting psychedelic compounds. “We are extremely pleased that our abstract was selected for presentation, as this is foundational research that will inform the selection of a potential future development candidate,” said Cybin CEO Doug Drysdale in the press release. “The Neuropsychiatric Drug Development Summit is a unique opportunity to engage with innovators in neuropsychiatry and to share ideas that ultimately drive the field forward.”

To view the full press release, visit https://ibn.fm/JRheH

About Cybin Inc.

Cybin is a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental-health conditions. Cybin’s goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug-discovery platforms, innovative drug-delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder; the company also has a research pipeline of investigational psychedelic-based compounds. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

About InvestorWire

InvestorWire (“IW”) is a specialized communications platform with a focus on advanced wire-grade press release syndication for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, IW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, IW brings its clients unparalleled recognition and brand awareness. IW is where breaking news, insightful content and actionable information converge.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorWire website applicable to all content provided by IW, wherever published or re-published: https://www.InvestorWire.com/Disclaimer

InvestorWire
Los Angeles, CA
www.InvestorWire.com
310.299.1717 Office
Editor@InvestorWire.com

InvestorWire is powered by IBN

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.